GT Medical Technologies, announced that it has raised $37 million in Series D financing round. The financing round was led ...

Digital health firms in the city raised $4 billion in 2024, up 60% from the previous year, according to a report released ...

Cystic fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

EVA Pharma of Africa, DNA Script and Quantoom Biosciences have signed a MoU to establish the mRNA production platform in Egypt.

Exo-Top was established under the jurisdiction of the State of Nevada. Basing Exo-Top in the U.S. offers key advantages, including proximity to strategic partners, access to a robust biopharma ...

Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, ...

The Company granted options to purchase 250,000 shares of Terns common stock to the new employee. The options have a 10-year term and an exercise price per share equal to $4.46, which was the closing ...

Cystic fibrosis drug developer Sionna Therapeutics hopes to join the IPO wave started by Metsera and Maze Therapeutics last ...

Amongst the flurry of corporate earnings and economy-shaking announcements from the newly elected U.S. administration, the U.S. IPO pipeline maintains its steady pace. This week, building materials ...

Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...

Monday saw the release of JMP Securities' latest industry overview for the biotechnology sector, which highlighted key events from January 2025. The report noted a modest resurgence in the sector, ...